{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:01:52Z","timestamp":1791464512128,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.medcli.2026.107621","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:44:37Z","timestamp":1790700277000},"page":"107621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enfermedad de Fabry m\u00e1s all\u00e1 del modelo cl\u00e1sico: expresi\u00f3n cl\u00ednica y retos diagn\u00f3sticos en mujeres"],"prefix":"10.1016","volume":"166","author":[{"given":"Olaya","family":"Huergo Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"M\u00e9ndez Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Ordieres Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"L\u00f3pez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2026.107621_bib0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13023-018-0792-8","article-title":"Fabry disease in the Spanish population: observational study with detection of 77 patients","volume":"10","author":"Vieitez","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2026.107621_bib0245","first-page":"47","article-title":"Characterization of the plasma proteomic profile of Fabry disease: potential sex- and clinical phenotype-specific biomarkers","volume":"269","author":"L\u00f3pez-Valverde","year":"2024","journal-title":"Transl Res J Lab Clin Med."},{"key":"10.1016\/j.medcli.2026.107621_bib0250","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.rce.2018.09.017","article-title":"Spanish multidisciplinary clinical practice guidelines for Anderson\u2013Fabry disease in adults I. Method and recommendations","volume":"219","author":"Calder\u00f3n Sandubete","year":"2019","journal-title":"Rev Clin Esp (Engl Ed)."},{"key":"10.1016\/j.medcli.2026.107621_bib0255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13023-022-02599-w","article-title":"The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants","volume":"18","author":"S\u00e1nchez","year":"2023","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2026.107621_bib0260","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13023-025-03922-x","article-title":"Fabry disease in females: organ involvement and clinical outcomes compared with the general population","volume":"20","author":"Hopkin","year":"2025","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2026.107621_bib0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/genes15010037","article-title":"Fabry disease in women: genetic basis available biomarkers, and clinical manifestations","volume":"15","author":"Izhar","year":"2023","journal-title":"Genes (Basel)."},{"key":"10.1016\/j.medcli.2026.107621_bib0270","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13023-025-03705-4","article-title":"Current status of the immunogenicity of enzyme replacement therapy in Fabry disease","volume":"20","author":"G\u00f3mez-Cerezo","year":"2025","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2026.107621_bib0275","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13023-024-03500-7","article-title":"Clinical management of female patients with Fabry disease based on expert consensus","volume":"20","author":"Brand","year":"2025","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2026.107621_bib0280","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00439-020-02199-3","article-title":"The Human Gene Mutation Database (HGMD\u00ae): optimizing its use in clinical genetics, disease biology, and data mining","volume":"139","author":"Stenson","year":"2020","journal-title":"Hum Genet."},{"key":"10.1016\/j.medcli.2026.107621_bib0285","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1536114","article-title":"Females with Fabry disease: an expert opinion on diagnosis, clinical management, current challenges and unmet needs","volume":"12","author":"Tuttolomondo","year":"2025","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.medcli.2026.107621_bib0290","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.medcli.2026.107621_bib0295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","article-title":"An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease","volume":"137","author":"Germain","year":"2022","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.medcli.2026.107621_bib0300","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose Fabry disease in clinical pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am J Med Sci."},{"key":"10.1016\/j.medcli.2026.107621_bib0305","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12574-017-0340-x","article-title":"Fabry disease","volume":"15","author":"Yuasa","year":"2017","journal-title":"J Echocardiogr."},{"key":"10.1016\/j.medcli.2026.107621_bib0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One."},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2026.107621_bib0315","doi-asserted-by":"crossref","first-page":"s10","DOI":"10.1590\/1806-9282.66.s1.10","article-title":"Fabry disease: genetics, pathology, and treatment","volume":"66","author":"Bernardes","year":"2020","journal-title":"Rev Assoc Med Bras (1992)."},{"key":"10.1016\/j.medcli.2026.107621_bib0320","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20240535i","article-title":"Fabry disease and its different phenotypes","volume":"122","author":"Antunes","year":"2025","journal-title":"Arq Bras Cardiol."},{"key":"10.1016\/j.medcli.2026.107621_bib0325","article-title":"Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation","volume":"22","author":"Azevedo","year":"2020","journal-title":"Mol Genet Metab Rep."},{"key":"10.1016\/j.medcli.2026.107621_bib0330","series-title":"GeneReviews\u00ae [Internet]","article-title":"Fabry Disease. [updated 2024 Apr 11]","author":"Mehta","year":"2002"},{"key":"10.1016\/j.medcli.2026.107621_bib0335","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3390\/genes14091804","article-title":"Sex differences in Anderson-Fabry cardiomyopathy: clinical, genetic, and imaging analysis in women","volume":"14","author":"Faro","year":"2023","journal-title":"Genes (Basel)."},{"key":"10.1016\/j.medcli.2026.107621_bib0340","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J Med Genet."},{"key":"10.1016\/j.medcli.2026.107621_bib0345","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.medcli.2026.107621_bib0350","first-page":"2","article-title":"Fabry disease in women: beyond the role of \u201ccarriers\u201d","volume":"4","author":"Barba-Romero M?","year":"2025","journal-title":"Rare Dis Orphan Drugs J."},{"key":"10.1016\/j.medcli.2026.107621_bib0355","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.medcli.2016.09.047","article-title":"Diagnosis and treatment of Fabry disease","volume":"148","author":"Ortiz","year":"2017","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2026.107621_bib0360","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/TCRM.S247814","article-title":"Diagnosis and screening of patients with Fabry disease","volume":"22","author":"Vardarli","year":"2020","journal-title":"Ther Clin Risk Manag."},{"key":"10.1016\/j.medcli.2026.107621_bib0365","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"10.1016\/j.medcli.2026.107621_bib0370","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-025-03600-y","article-title":"Impact of enzyme replacement therapy and migalastat on disease progression in females with Fabry disease","volume":"20","author":"Lenders","year":"2025","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2026.107621_bib0375","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet."},{"key":"10.1016\/j.medcli.2026.107621_bib0380","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12325-024-03062-x","article-title":"Influence of treatment effect modifiers in fabry disease: a systematic literature review","volume":"42","author":"Azimpour","year":"2025","journal-title":"Adv Ther."},{"key":"10.1016\/j.medcli.2026.107621_bib0385","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.rce.2018.03.018","article-title":"Tratamiento en la enfermedad de Fabry","volume":"218","author":"L\u00f3pez Rodr\u00edguez","year":"2018","journal-title":"Rev Cl\u00edn Esp."},{"key":"10.1016\/j.medcli.2026.107621_bib0390","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.medcli.2026.107621_bib0395","article-title":"Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease","volume":"12","author":"Germain","year":"2024","journal-title":"Front Genet."},{"key":"10.1016\/j.medcli.2026.107621_bib0400","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jmg-2023-109445","article-title":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study","volume":"61","author":"Wallace","year":"2024","journal-title":"J Med Genet."},{"key":"10.1016\/j.medcli.2026.107621_bib0405","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12795","article-title":"A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies","volume":"48","author":"Holida","year":"2025","journal-title":"J Inherit Metab Dis."},{"key":"10.1016\/j.medcli.2026.107621_bib0410","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13023-023-02803-5","article-title":"Safety and tolerability of agalsidase beta infusions shorter than 90\u00a0min in patients with Fabry disease: post-hoc analysis of a Japanese post-marketing study","volume":"18","author":"Lee","year":"2023","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2026.107621_bib0415","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"El Dib","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.medcli.2026.107621_bib0420","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med."},{"key":"10.1016\/j.medcli.2026.107621_bib0425","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet Med."},{"key":"10.1016\/j.medcli.2026.107621_bib0430","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: A review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.medcli.2026.107621_bib0435","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2174\/1570159X20666220601124117","article-title":"Fabry disease: current and novel therapeutic strategies. a narrative review","volume":"21","author":"Palaiodimou","year":"2023","journal-title":"Curr Neuropharmacol."},{"key":"10.1016\/j.medcli.2026.107621_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.medcli.2026.107621_bib0445","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41467-025-68256-5","article-title":"Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension","volume":"17","author":"Nordbeck","year":"2026","journal-title":"Nat Commun."},{"key":"10.1016\/j.medcli.2026.107621_bib0450","first-page":"106","article-title":"Evaluating the metabolic basis of \u03b1-Gal A mRNA therapy for Fabry disease: preclinical evidence of protein expression and substrate reduction in a Fabry disease model","volume":"13","author":"Zhang","year":"2024","journal-title":"Biology (Basel)."},{"key":"10.1016\/j.medcli.2026.107621_bib0455","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40259-025-00723-3","article-title":"Progress and challenges in the treatment of Fabry disease","volume":"39","author":"Lenders","year":"2025","journal-title":"BioDrugs."},{"key":"10.1016\/j.medcli.2026.107621_bib0460","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.medcli.2026.107621_bib0465","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.medcli.2018.10.039","article-title":"Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy","volume":"153","author":"Barba-Romero M\u00c1","year":"2019","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2026.107621_bib0470","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70142","article-title":"Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey","volume":"56","author":"Hughes","year":"2026","journal-title":"Eur J Clin Invest."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326002721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326002721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:41:25Z","timestamp":1791463285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775326002721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0025775326002721"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107621","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfermedad de Fabry m\u00e1s all\u00e1 del modelo cl\u00e1sico: expresi\u00f3n cl\u00ednica y retos diagn\u00f3sticos en mujeres","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107621"}}